4Filing Date: Sep 14, 2026

Moderna (MRNA)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0001682852-26-000174
Total Value$5.30M
Trades4
Insiders1

Transaction Details

Mock James M
Chief Financial Officer·Direct
Exercise · Dispose
Stock Option (Right to Buy)Derivative
Shares-19.84K
Price$0.00
Total Value$0
Shares Owned After43.64K
Transaction DateSep 10, 2026
Exercise Price$30.96
ExpiresMar 1, 2035
10b5-1
Footnotes ▸

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. | 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Mock James M
Chief Financial Officer·Direct
Sell · Dispose
Common Stock
Shares-15.00K
Price$134.49
Total Value$2.02M
Shares Owned After59.38K
Transaction DateSep 10, 2026
10b5-1
Footnotes ▸

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.

Mock James M
Chief Financial Officer·Direct
Exercise · Acquire
Common Stock
Shares+19.84K
Price$30.96
Total Value$614.1K
Shares Owned After94.21K
Transaction DateSep 10, 2026
10b5-1
Footnotes ▸

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.

Mock James M
Chief Financial Officer·Direct
Sell · Dispose
Common Stock
Shares-19.84K
Price$134.49
Total Value$2.67M
Shares Owned After74.38K
Transaction DateSep 10, 2026
10b5-1
Footnotes ▸

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.

Post-Transaction Holdings

Mock James M · Chief Financial Officer
SecuritySharesChange
Common Stock59.38K-15.00K (-20.17%)
Stock Option (Right to Buy)43.64K-19.84K (-31.25%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-09-10 10b5-1 Pre-arranged Plan: Yes --- Issuer --- Name: Moderna, Inc. (MRNA) CIK: 0001682852 --- Reporting Owner --- Name: Mock James M CIK: 0001736359 Role: Officer (Chief Financial Officer) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-09-10 | Code: M (Exercise of derivative) Shares: +19,836 | Price: $30.96 Total Value: $614,122.56 Shares Owned After: 94,211 | Ownership: D (Direct) Footnotes: [F1] The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. [Transaction #2] Security: Common Stock Date: 2026-09-10 | Code: S (Open market sale) Shares: -19,836 | Price: $134.49 Total Value: $2,667,743.64 Shares Owned After: 74,375 | Ownership: D (Direct) Footnotes: [F1] The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. [Transaction #3] Security: Common Stock Date: 2026-09-10 | Code: S (Open market sale) Shares: -15,000 | Price: $134.49 Total Value: $2,017,350.00 Shares Owned After: 59,375 | Ownership: D (Direct) Footnotes: [F1] The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. --- Derivative Transactions --- [Transaction #1] Security: Stock Option (Right to Buy) Date: 2026-09-10 | Code: M (Exercise of derivative) Shares: -19,836 | Price: $0.00 Exercise Price: $30.96 Exercisable: N/A | Expires: 2035-03-01 Shares Owned After: 43,642 | Ownership: D (Direct) Footnotes: [F1] The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. [F2] 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. --- Footnotes (Complete Index) --- F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. F2: 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. --- Signature --- /s/ /s/ James Dillon, As Attorney-in-Fact (2026-09-14)

keid analysis is for reference only and does not constitute investment advice.